Kornimate/medical-research-clean huggingface dataset:
covid 19 viral clearance among the infected healthcare workers in assiut university hospitals

Conditions: Infection, Coronavirus

Summary: this work was aimed to determine the time of covid 19 viral clearance in healthcare workers, assessment of clinical presentation and severity of covid 19 infection among healthcare workers and discover relation between the time of covid 19 viral clearance resolution of symptoms

covid-19 has been spreading rapidly globally, with a considerable impact on global morbidity, mortality and healthcare utilization. this viral disease is caused by the coronaviruses (cov) which belong to the genus'coronavirus' of the coronaviridae family. coronaviruses are enveloped positive strand rna viruses with the largest known rna genomes-30-32 kb-with a 50 -cap structure and 30 -poly-a tail (lei et al.2018). the transcription works through the replication-transcription complex (rct) organized in double-membrane vesicles and via the synthesis of subgenomic rnas (sgrnas) sequences. of note, transcription termination occurs at transcription regulatory sequences, located between the so-called open reading frames (orfs). in the atypical cov genome, at least six orf scan could be present (woo et al., 2020) . health workers are at the front line of the covid-19 outbreak response and as such are exposed to hazards that put them at risk of infection (li e al.,2020). thus keeping the implementation of infection prevention and control (ipc) and its knowledge and practice are of great importance in healthcare settings to protect them from infections (wang et al., 2020).

Eligibility criteria:
inclusion criteria: * covid 19 infected healthcare workers. exclusion criteria: * risky healthcare workers (diabetic hypertensive and more than 50 years)
a phase 2 study to evaluate efficacy and safety of al002 in participants with early alzheimer's disease

Conditions: Alzheimer Disease

Summary: a phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of al002 in participants with early alzheimer's disease.

this is a phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of al002 administered intravenously in participants with early alzheimer's disease.

Eligibility criteria:
inclusion criteria: * diagnosis of early ad including evidence of brain amyloidosis by csf or pet * mmse score ≥ 20 points, cdr global score of 0.5 - 1.0, and rbans score on the dmi ≤95. * study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week * written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker). exclusion criteria: * dementia due to a condition other than ad including, but not limited to, ftd, parkinson's disease, dementia with lewy bodies, huntington disease, or vascular dementia. - dementia due to a condition other than ad including, but not limited to, ftd, parkinson's disease, dementia with lewy bodies, huntington disease, or vascular dementia. * known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. * current uncontrolled hypertension, diabetes mellitus or thyroid disease. clinically significant heart disease, liver disease or kidney disease. * history or evidence of clinically significant brain disease other than ad. * females who are pregnant or breastfeeding, or planning to conceive within the study period. * any experimental vaccine or gene therapy. * history of unresolved cancer. * current use of anticoagulant medications. * residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care. * participant is positive for presence of apoe e4/e4 genotype.
safety, pharmacokinetic study of rvx000222 in healthy subjects and subjects with low hdl cholesterol

Conditions: Dyslipidemia; Atherosclerosis; Acute Coronary Syndrome; Cardiovascular Disease

Summary: the purpose of this study is to investigate an oral formulation of rvx000222 for safety, pharmacokinetic and efficacy in healthy subjects.

one-third of the us population, almost 80 million adults, have cardiovascular disease and mortality associated with heart disease which still remains a leading cause of death around the world. the major risk factors for cardiovascular disease associated with atherosclerosis is dyslipidemia, characterized by high levels of low density lipoprotein (ldl) and/or low levels of high density lipoprotein (hdl). hdl has a well established role in atherosclerosis and cardiovascular disease protection. hdl mediates the removal of cholesterol from the atherosclerotic plaques for elimination from the body. the major component of hdl consists of apolipoprotein a-i (apoa i). recent intervention studies with synthetic hdl particles and recombinant apoa-i have shown that hdl has the capacity to reverse coronary atherosclerosis. rvx000222 is a member of a novel class of small molecules that are candidates for the treatment of dyslipidemia by increasing plasma levels of apoa-i and hdl.

Eligibility criteria:
inclusion criteria: * subjects who meet the following criteria may be enrolled: 1. be men or women between 18 and 65 years old, inclusive 2. weigh between 60 kg and 110 kg, inclusive, and have a bmi ≥25 kg/m2. 3. healthy volunteers with normal or low hdl 4. if female, non-pregnant (as determined by a negative serum pregnancy test at screening), non-lactating, and not of childbearing-potential or willing to practice an acceptable form of birth control. if male, be willing to practice an acceptable form of birth control. exclusion criteria: * subjects who meet any of the following criteria will not be enrolled: 1. have presently, or have a history of, clinically significant disease, including cardiovascular, gastrointestinal, renal, hepatic, pulmonary, endocrine, hematologic, vascular, immunologic, metabolic, neurological, or collagen disease, as judged by the investigator. 2. have active cholecystitis or gallbladder symptoms within 60 days prior to check-in (subjects who have had a cholecystectomy are not excluded from this study). 3. have had a clinically significant illness, in the opinion of the investigator, within 30 days prior to check-in. 4. have hypertension that is currently being treated, or uncontrolled hypertension 5. have a serum creatinine \>1.5 mg/dl, hemoglobin \<11.2 g/dl, or white blood cell count \<4000/μl. 6. have positive test results for hiv, hepatitis a, b, or c. 7. have a positive result on drug screen testing.

Keywords: cholesterol high density lipoprotein dyslipidemia atherosclerosis apolipoprotein a-i
peace: comparing chronic pain treatment options

Conditions: Chronic Pain; Musculoskeletal Pain; Fibromyalgia; Pain Management

Summary: the purpose of this study is to compare two types of acupuncture with usual care on treating chronic pain. this study has three groups. two groups will received acupuncture. one group will receive usual standard of care for 12 weeks and then will receive acupuncture. acupuncture is an ancient chinese technique of using very thin needles inserted in the skin to treat different symptoms and illness, and to promote healing. each group will undergo a different method of needle administration.


Eligibility criteria:
inclusion criteria: * english speaking * age \>/= 18 years or older * having musculoskeletal pain, defined as regional (joints, extremities, back, neck) or more generalized (fibromyalgia or chronic widespread pain) * having a pain rating of 4 or greater in worst pain on a 1-10 numerical rating scale in the preceding week (patients with a neuropathic component to their pain that involves the extremities or back will be eligible) * having had pain for at least 3 months and at least 15 days with pain in the preceding 30 days * a diagnosis of cancer with no restrictions placed on type of cancer, other than that patients with metastatic disease will be excluded. eligibility criteria are not restricted to msk confirmed biopsy/diagnosis. participating institution's testing is sufficient for other study sites. * complete active treatment (surgery, chemotherapy, and/or radiotherapy) at least one month prior to study initiation (patients on continued hormone treatment will not be excluded). exclusion criteria: * have non-musculoskeletal pain syndromes (headache, facial pain, chest pain, visceral abdominal pain) if these are the sole source of pain, but can be present as co-morbid conditions as long as a patient has a primary musculoskeletal pain condition defined s above. * inflammatory arthritis that require disease modifying drugs (e.g. rheumatoid arthritis) * phantom limb pain * patients with a history of metastatic cancer who are not currently ned * have a pending pain-related va or social security or worker's comp disability claim by self-report * have an implanted electronically charged medical device

Keywords: acupuncture pain chronic pain pain management 16-1579
vitamin d for improving metabolic control and depressive symptoms

Conditions: Depressive Symptoms; Diabetes

Summary: this study will examine whether weekly vitamin d supplementation in women with significant depressive symptoms and diabetes will exhibit improved mood and metabolic control. if supplementation with vitamin d is beneficial, it will be a simple and cost-effective method for treatment. women will be targeted since they have greater depression and worse metabolic control than men with diabetes.


Eligibility criteria:
inclusion criteria: 1. women aged 18 and older 2. medically stable type 2 diabetes with hba1c \<9%. 3. significantly elevated depressive symptoms as measured by a score greater than or equal to 14 using the center for epidemiologic studies depression tool (ces-d. exclusion criteria: 1. vitamin d levels of 32 ng/dl or greater 2. malabsorption problems (e.g., crohn's disease, celiac sprue) 3. hypercalcemia-level greater than 10.5 mg/dl 4. severe complications of diabetes (amputation, blindness, or renal problems) 5) women with low thyroid function 6) active suicidal ideation, a history of bipolar depression, psychotic disorders, and current alcohol or substance disorders. active treatment for depression (e.g., antidepressant therapy) will not be exclusion criteria 7) any serious chronic illness that may impact on their health-related quality of life and treatment effect 8) women who are pregnant 9) women who have had bariatric surgery.
metformin treatment in progressive multiple sclerosis

Conditions: Secondary Progressive Multiple Sclerosis; Primary Progressive Multiple Sclerosis

Summary: the purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

this will be a single site 1:1 randomized, placebo controlled trial of metformin treatment vs matching placebo in 44 men and women with primary progressive multiple sclerosis and secondary multiple sclerosis, without diabetes, not treated with metformin aged 30-65. the trial will last 12 months and have 3 study visits, baseline, 6 months, and 12 months. the trial will be preceded by a screening period. over the initial 30 day titration period subjects will be titrated from 500 mg a day to 2,000 mg of metformin in increments of 500 mg every 10 days. patients will remain on their tolerated dose and included in analysis on an intent to treat basis. brain mri, cognitive testing and clinical measures will be collected at baseline, month 6 and month 12. oct will be collected at baseline and month 12. the primary outcomes are the following safety outcomes: 1) number of patients with adverse events 2) number of patients with laboratory abnormalities 3) number of patients with new t2 lesions on mri. the secondary outcomes include reduction in localized cortical thinning on brain mri; reduction in thalamic atrophy on brain mri. further exploratory outcomes include 1) improvement in sdmt-oral score, 2) improvement in cvlt-ii score, 3) improvement in pacc score 4) improvement in pasat score. exploratory outcomes include 1) decrease in plasma neurofilament light chain levels, 2) reginal nerve fiber layer preservation on oct, 3) ganglion cell inner plexiform layer preservation, and 4) percentage of phase rim lesions.

Eligibility criteria:
inclusion criteria: 1. patient signed informed consent. 2. age 30-65 3. primary progressive multiple sclerosis or secondary progressive multiple sclerosis as defined by the 2017 mcdonald criteria 4. intent to maintain current ms disease modifying treatment through the trial duration exclusion criteria: 1. clinical relapse in prior 12 months 2. new t2 lesion or gadolinium enhancing lesion in prior 12 months 3. glucocorticoid use in prior six months outside the context of premedication for disease modifying treatment 4. changes in disease modifying therapy in prior three months 5. plans to change current disease modifying therapy 6. contraindication to mri, inability to tolerate mri 7. use of metformin for any other indication 8. renal dysfunction (gfr \< 60) 9. hepatic dysfunction (ast or alt \> 1.5 x upper limit of normal) 10. b12 deficiency 11. prior poor reaction to metformin 12. congestive heart failure 13. alcohol abuse 14. metabolic acidosis 15. females who are pregnant or who plan to become pregnant during the 12 months of enrollment, or who wish to breastfeed during any part of the 12 months of enrollment 16. concomitant use of drugs with drug-drug interactions with metformin 17. previous adverse effect with metformin treatment

Keywords: multiple sclerosis demyelinating disease
a study for evaluation of immunogenicity and reactogenicity of fluarixtm / influsplit ssw® 2009/2010 in adults

Conditions: Influenza

Summary: this study is designed to test the immunogenicity and reactogenicity of the fluarixtm/influsplit ssw® influenza vaccine containing the influenza strains recommended for the 2009-2010 season.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * a male or female aged 18 years or above at the time of the vaccination. * written informed consent obtained from the subject. * healthy subjects or with well-controlled chronic diseases as established by medical history and clinical examination before entering into the study. * if the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series. exclusion criteria: * use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the vaccination or planned use during the study period. * chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose. * administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or planned during the study. * administration of an influenza vaccine within 6 months preceding the study start. * administration of an influenza vaccine other than the study vaccine during the entire study * clinically or virologically confirmed influenza infection within 6 months preceding the study start * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * acute disease at the time of enrolment. * acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * not stabilized or clinically serious chronic underlying disease. * lactating female. * history of chronic alcohol consumption and/or drug abuse. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * any condition which, in the opinion of the investigator, prevents the subject from participation in the study.

Keywords: influenza
transradial access for ruptured intracranial aneurysms embolization

Conditions: Transradial Access

Summary: the goal of this clinical trail is to compare the difference between transradial access (tra) and transfemoral access(tfa) for ruptured intracranial aneurysms embolization. the main question it aims to answer is: whether is tra not inferior to tfa？ in the experimental group, the transradial access (tra) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm; in the control group, transfemoral access (tfa) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysms.the two groups of patients received an oral loading dose of aspirin (300mg) plus clopidogrel (300mg) on the day of surgery, while patients who were unable to take orally were given nasal feeding. during the operation, systemic heparinization was performed with a starting dose of 75u/kg intravenous injection, and the injection was halved every 1h until 1000u. after the operation, protamine neutralizing heparin (1mg protamine neutralizing 100u heparin) was used.


Eligibility criteria:
inclusion criteria: 1. the age is between 18 and 75 years old. 2. receiving interventional embolization treatment for intracranial aneurysms. 3. ct scan of the skull shows subarachnoid hemorrhage, and cta or dsa of the skull shows the presence of an intracranial aneurysm, and it is determined to be aneurysm-related subarachnoid hemorrhage after evaluation by a neurosurgical specialist. 4. at least one side of the bilateral radial arteries can be used to establish surgical access. 5. evaluation of radial artery patency: barbeau test type a-c . 6. hunt-hess grade 1-3, glasgow coma score ≥ 8. 7. agreed to participate in this study and willing to cooperate with follow-up. - exclusion criteria: 1. preoperative upper limb ultrasound or dsa showed radial artery spasm and arteriovenous fistula. 2. artery cta or dsa showed vascular anatomical abnormalities such as axillary artery occlusion, and acute angle between the left common carotid artery and the subclavian artery, which may affect the operation. 3. the patient's condition is serious and may die or remain in a coma after surgery, as assessed by a specialist. 4. received radial or femoral artery puncture examination or treatment within 1 month. 5. the patient refused to participate in the study or cooperate with follow-up.

Keywords: transradial access ruptured intracranial aneurysms intervention
posterior cad/cam cobalt-chromium alloy single crowns: 4-year prospective clinical study

Conditions: Single Tooth Lost

Summary: objectives - to evaluate the 4-year clinical outcomes of ceramic veneered computer aided design/computer aided manufacturing (cad/cam) co-cr single crowns supported by natural teeth in posterior regions. material and methods - eighty-nine patients were provided with 120 ceramic veneered cad/cam co-cr single crowns replacing either premolars and molars. specific inclusion criteria were needed and tooth preparations were standardized and performed by 2 expert prosthodontists. cad/cam co-cr frameworks were fabricated and veneered with ceramics. the restorations were cemented using a eugenol-free zinc oxide luting agent. the patients were recalled after 1, 6, 12, 24, 36 and 48 months. the survival and success of the restorations were evaluated. the technical and esthetic outcomes were examined using the united states public health service criteria. the biologic outcomes were analyzed at abutment and contralateral teeth and descriptive statistics were performed.


Eligibility criteria:
inclusion criteria: * good general health * american society of anesthesiologists (asa) asa i or asa ii condition; periodontal health * angle class i occlusal relationship * minimum of 10 couples of opponent teeth * good oral hygiene * no evident signs of parafunctions and/or temporomandibular disorders. * periodontal health of abutment teeth (absence of tooth mobility, absence of furcation involvement); * proper positioning of abutment teeth in the dental arch (tooth axis adequate for a sc) * sufficient occlusal-cervical height of the clinical crown of abutment teeth (≥ 4 mm) for the retention of a sc * vital or endodontically treated to a clinically sound state abutment teeth; * abutment teeth opposing natural teeth. exclusion criteria: * high caries activity * presence of periodontal disease on the abutment tooth * occlusal-cervical height of the abutment tooth \< 4 mm * reduced interocclusal distance or supraerupted opposing teeth * unfavorable crown-to-root ratio * severe were facets, clenching and/or bruxism * presence of removable partial dentures (rpds) * pregnancy or lactation * alcohol and/or drug addiction
preliminary outcome of tecar on stress urinary incontinence, pelvic floor strength and sexual satisfaction in women with vaginal relaxation syndrome

Conditions: STRESS URINARY INCONTINENCE; VAGINAL RELAXATION SYNDROME

Summary: forty women aged 50-60 years with a body mass index (bmi) of 25 kg/m2 to 30 kg/m2, who complain of stress urinary incontinence and vaginal laxity, will be separated randomly into two equivalent groups. in group (a) 20 women will receive tecar therapy for 15 min and pelvic floor exercise for 20 min, while in group (b), 20 females will receive sham treatment for 15 min and pelvic floor exercise for 20 min twice per week for 8 weeks. both groups wil be assessed using a perineometer as an assessment tool for pelvic floor muscle strength muscles and the visual analog scale, iciq-ui short form questionnaire about the frequency of urinary incontinence symptoms, millheiser sexual satisfaction scale, and the sexual quality of life questionnaire-female (sqol-f) to assess sexual satisfaction by each patient before, after 4 weeks, and after 8 weeks of treatment


Eligibility criteria:
inclusion criteria: * participants are multipara at least two times with sexual activity for at least 1/month with normal cell cytology (pap smear), integrity of the vaginal canal mucosa, and negative urine culture (without injuries or bleeding). exclusion criteria: * pregnancy, use of photosensitive medicines, vaginal bleeding injury or infection in the treated area, and use of an iud.

Keywords: vaginal relaxation syndrome tecar therapy